{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:07:30Z","timestamp":1778627250441,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,4,21]],"date-time":"2027-04-21T00:00:00Z","timestamp":1808265600000},"content-version":"am","delay-in-days":385,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","award":["17K11517"],"award-info":[{"award-number":["17K11517"]}],"id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jpedsurg.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pediatric Surgery"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.jpedsurg.2025.162771","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T16:17:31Z","timestamp":1761841051000},"page":"162771","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Combined MEK and YAP inhibition in a mouse model of neuroblastoma: A promising approach for minimal residual disease"],"prefix":"10.1016","volume":"61","author":[{"given":"Ryota","family":"Tsuji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8886-2515","authenticated-orcid":false,"given":"Shigehisa","family":"Fumino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyokazu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shohei","family":"Takayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1485-2231","authenticated-orcid":false,"given":"Masafumi","family":"Iguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masakazu","family":"Takemoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuro","family":"Tajiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jpedsurg.2025.162771_bib1","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/jjco\/hyx176","article-title":"Neuroblastoma","volume":"48","author":"Nakagawara","year":"2018","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.jpedsurg.2025.162771_bib2","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1093\/annonc\/mdx125","article-title":"Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients","volume":"28","author":"Vidal","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jpedsurg.2025.162771_bib3","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1093\/annonc\/mdx401","article-title":"BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives","volume":"28","author":"Sanz-Garcia","year":"2017","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.jpedsurg.2025.162771_bib4","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1038\/ng.3333","article-title":"Relapsed neuroblastomas show frequent RAS-MAPK pathway mutations","volume":"47","author":"Eleveld","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.jpedsurg.2025.162771_bib5","first-page":"23","article-title":"Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1\/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo","volume":"39","author":"Yamaguchi","year":"2011","journal-title":"Int J Oncol"},{"key":"10.1016\/j.jpedsurg.2025.162771_bib6","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00383-020-04806-w","article-title":"Immunohistochemical staining of phosphorylated-ERK in post-chemotherapeutic samples is a potential predictor of the prognosis of neuroblastoma","volume":"37","author":"Tanaka","year":"2021","journal-title":"Pediatr Surg Int"},{"issue":"12","key":"10.1016\/j.jpedsurg.2025.162771_bib7","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1016\/j.jpedsurg.2018.08.026","article-title":"In vivo effects of short- and long-term MAPK pathway inhibition against neuroblastoma","volume":"53","author":"Takeuchi","year":"2018","journal-title":"J Pediatr Surg"},{"issue":"6","key":"10.1016\/j.jpedsurg.2025.162771_bib8","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jpedsurg.2021.03.031","article-title":"Anti-relapse effect of trametinib on a local minimal residual disease neuroblastoma mouse model","volume":"56","author":"Togashi","year":"2021","journal-title":"J Pediatr Surg"},{"issue":"24","key":"10.1016\/j.jpedsurg.2025.162771_bib9","doi-asserted-by":"crossref","first-page":"6204","DOI":"10.1158\/0008-5472.CAN-19-1415","article-title":"YAP1 mediates resistance to MEK1\/2 inhibition in neuroblastomas with hyperactivated RAS signaling","volume":"79","author":"Coggins","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.jpedsurg.2025.162771_bib10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.bbrc.2021.07.028","article-title":"The synergistic antitumor effect of combination therapy with a MEK inhibitor and YAP inhibitor on pERK-positive neuroblastoma","volume":"570","author":"Takemoto","year":"2021","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"10.1016\/j.jpedsurg.2025.162771_bib11","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jpedsurg.2016.02.066","article-title":"A novel minimal residual disease model of neuroblastoma in mice","volume":"51","author":"Jackson","year":"2016","journal-title":"J Pediatr Surg"},{"issue":"8","key":"10.1016\/j.jpedsurg.2025.162771_bib12","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/ng.3349","article-title":"Mutational dynamics between primary and relapse neuroblastomas","volume":"47","author":"Schramm","year":"2015","journal-title":"Nat Genet"},{"issue":"9","key":"10.1016\/j.jpedsurg.2025.162771_bib13","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1038\/ng.3921","article-title":"Heterogeneity of neuroblastoma cell identity defined by transcriptional circuitries","volume":"49","author":"Boeva","year":"2017","journal-title":"Nat Genet"},{"key":"10.1016\/j.jpedsurg.2025.162771_bib14","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1146\/annurev-biochem-013118-111829","article-title":"The Hippo pathway: biology and pathophysiology","volume":"88","author":"Ma","year":"2019","journal-title":"Annu Rev Biochem"},{"issue":"4","key":"10.1016\/j.jpedsurg.2025.162771_bib15","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.devcel.2010.09.011","article-title":"The Hippo signaling pathway in development and cancer","volume":"19","author":"Pan","year":"2010","journal-title":"Dev Cell"},{"issue":"5","key":"10.1016\/j.jpedsurg.2025.162771_bib16","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/neuonc\/noab244","article-title":"Anti-invasive efficacy and survival benefit of the YAP-TEAD inhibitor Verteporfin in preclinical glioblastoma models","volume":"24","author":"Barrette","year":"2022","journal-title":"Neuro Oncol"},{"issue":"2","key":"10.1016\/j.jpedsurg.2025.162771_bib17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1158\/1535-7163.MCT-17-0560","article-title":"A novel YAP1 inhibitor targets CSCs-enriched radiation resistant cells and exerts strong antitumor activity in esophageal adenocarcinoma","volume":"17","author":"Song","year":"2018","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"10.1016\/j.jpedsurg.2025.162771_bib18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11060-021-03699-6","article-title":"Targeting the YAP-TEAD interaction interface for therapeutic intervention in glioblastoma","volume":"152","author":"Saunders","year":"2021","journal-title":"J Neuro Oncol"},{"issue":"2","key":"10.1016\/j.jpedsurg.2025.162771_bib19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11060-021-03699-6","article-title":"Targeting the YAP-TEAD interaction interface for therapeutic intervention in glioblastoma","volume":"152","author":"Saunders","year":"2021","journal-title":"J Neuro Oncol"},{"issue":"1","key":"10.1016\/j.jpedsurg.2025.162771_bib20","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ccell.2019.12.006","article-title":"Treatment-induced tumor dormancy through YAP-mediated transcriptional reprogramming of the apoptotic pathway","volume":"37","author":"Kurppa","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jpedsurg.2025.162771_bib21","article-title":"Senesce to survive: YAP-Mediated dormancy escapes EGFR\/MEK inhibition","author":"Bado","year":"2019","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.jpedsurg.2025.162771_bib22","doi-asserted-by":"crossref","first-page":"2240678","DOI":"10.1080\/2162402X.2023.2240678","article-title":"The yes-associated protein (YAP) is associated with resistance to anti-GD2 immunotherapy in neuroblastoma through downregulation of ST8SIA1","volume":"12","author":"Pilgrim","year":"2023","journal-title":"Oncoimmunology"}],"container-title":["Journal of Pediatric Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022346825006189?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022346825006189?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:08:15Z","timestamp":1778623695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022346825006189"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0022346825006189"],"URL":"https:\/\/doi.org\/10.1016\/j.jpedsurg.2025.162771","relation":{},"ISSN":["0022-3468"],"issn-type":[{"value":"0022-3468","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined MEK and YAP inhibition in a mouse model of neuroblastoma: A promising approach for minimal residual disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Pediatric Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpedsurg.2025.162771","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"162771"}}